Pluto Bio, a Denver-based company providing AI-driven multi-omics analysis solutions to the pharma industry, has secured $3.6 million in new funding. The capital comes from investors such as Kickstart and Silverton Partners.
Pluto Bio’s platform provides a secure and collaborative environment for scientists to explore large datasets, run bioinformatics pipelines and generate visualizations without having to write code. It allows scientists to run proprietary analyses on both public and private datasets, which can assist with critical steps in the early-mid drug discovery process.
The funding will help Pluto enhance its AI agents and copilots, expand integrations with other research and development tools and build out commercial roles to support broader deployment into new therapeutic areas and modalities.
